Last reviewed · How we verify
Filgrastim-sndz
Filgrastim-sndz is a granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow.
Filgrastim-sndz is a granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells in bone marrow. Used for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies, Severe chronic neutropenia, Mobilization of peripheral blood progenitor cells for autologous transplantation.
At a glance
| Generic name | Filgrastim-sndz |
|---|---|
| Also known as | Filgrastim Biosimilar Filgrastim-sndz, Zarxio |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (GCSFR) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Filgrastim-sndz binds to G-CSF receptors on hematopoietic cells, promoting neutrophil production and release from the bone marrow into peripheral circulation. This increases neutrophil counts and enhances their functional activity, helping to reduce the risk and duration of severe neutropenia in patients receiving myelosuppressive chemotherapy or undergoing bone marrow transplantation.
Approved indications
- Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies
- Severe chronic neutropenia
- Mobilization of peripheral blood progenitor cells for autologous transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Elevated uric acid
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Filgrastim-sndz CI brief — competitive landscape report
- Filgrastim-sndz updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI